title: Anticancer and antioxidative effects of micronized zeolite clinoptilolite.
abstract: BACKGROUND
  Treatment of cancer-bearing mice and dogs with micronized zeolite clinoptilolite (MZ) led to improvement of the overall health status, prolongation of life span and decrease of tumor size in some cases. It also reduced lipid peroxidation in the liver of mice.
  
  
  METHODS
  The experiments were performed on various tumor cell cultures and tumor-bearing animals. Immunohistochemistry was used to analyze if MZ could interfere with Doxorubicin-induced lipid peroxidation and consequential production of 4-hydroxynonenal (HNE).
  
  
  RESULTS
  MZ reduced the metabolic rate of cancer cells and increased binding of HNE to albumin in vitro. It selectively reduced generation of HNE in vivo in tumor stroma after Doxorubicin treatment leaving onset of lipid peroxidation intact in malignant cells. Combined treatment with Doxorubicin and MZ resulted in strong reduction of the pulmonary metastasis count increasing anticancer effects of Doxorubicin.
  
  
  CONCLUSIONS
  Interference of MZ with lipid peroxidation might explain some of the beneficial effects of this particular zeolite in combined cancer therapy.
authors.affiliation: Ruder Boskovic Institute, Division of Molecular Medicine, Bijenicka 54, HR-10000 Zagreb, Croatia.
authors.forename: Neven
authors.initials: N
authors.lastname: Zarkovic
authors.forename: Kamelija
authors.initials: K
authors.lastname: Zarkovic
authors.forename: Marijeta
authors.initials: M
authors.lastname: Kralj
authors.forename: Suzana
authors.initials: S
authors.lastname: Borovic
authors.forename: Senka
authors.initials: S
authors.lastname: Sabolovic
authors.forename: Marija Poljak
authors.initials: MP
authors.lastname: Blazi
authors.forename: Ana
authors.initials: A
authors.lastname: Cipak
authors.forename: Kresimir
authors.initials: K
authors.lastname: Pavelic
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000447:Aldehydes / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology; D002277:Carcinoma / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D006367:HeLa Cells / Q000187:drug effects; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology; D015227:Lipid Peroxidation / Q000187:drug effects*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000517:prevention & control / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D051379:Mice; D008808:Mice, Inbred CBA; D018384:Oxidative Stress; D010190:Pancreatic Neoplasms / Q000473:pathology; D010316:Particle Size; D011485:Protein Binding / Q000187:drug effects; D017382:Reactive Oxygen Species; D015290:Second Messenger Systems; D012709:Serum Albumin / Q000378:metabolism; D014961:X-Ray Diffraction; D017641:Zeolites / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000447:Aldehydes; D000970:Antineoplastic Agents; D000975:Antioxidants; D017382:Reactive Oxygen Species; D012709:Serum Albumin; C083175:clinoptilolite; D017641:Zeolites; D004317:Doxorubicin; C027576:4-hydroxy-2-nonenal